Dexamethasone for PENG Block in Total Hip Arthroplasty
CompletedPhase 4NCT06470139
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
Effect of adding Dexamethasone to Periarticular Nerve Group Block in Patients undergoing Total Hip Arthroplasty
Study details
- Official title
- Pericapsular Nerve Group (PENG) Block with Ropivacaine Vs Ropivacaine and Dexamethasone in Total Hip Arthroplasty: a Randomized Controlled Trial
- Conditions
- Hip Osteoarthritis
- Hip Arthropathy
- Hip Pain Chronic
- Interventions
- Drug: Ropivacaine 0.2% Injectable Solution
- Drug: Ropivacaine 0.2% Injectable Solution + 4mg Dexamethasone
- Sponsor
- Poznan University of Medical Sciences
- Start date
- 2024-08-13
- Primary completion
- 2025-01-15
- Sex
- All
- Age range
- from 65 Years to 100 Years
- Results posted
- No results posted in this snapshot
- Countries
- Poland
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * patients scheduled for total hip arthroplasty * patients aged \>65 and \<100 years * patients able to provide informed consent * patients able to reliably report symptoms to the research team Exclusion Criteria: * inability to provide first-party consent due to cognitive impairment or a language barrier
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT06470139